Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan)

You are here: Home / Statistics / Comparative statistics by registry

Comparative statistics by cancer registry

Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site

(Lampang, Thailand, 1990-2000 cases followed-up until 2003)

Click on cancer site (ICD-10 code) for comparison

Site	ICD-10	No. of cases included	Complete FU		Incomplete FU: loss to FU						% with Complete FU at 5 years	Median FU (in months)
			Alive/dead	At end of FU	No.	%	% lost to FU: years from diagnosis
			No.	%	No.	%	<1	1-3	3-5	>5
C00	Lip	33	32	97.0	1	3.0	0.0	0.0	0.0	3.0	100.0	72.8
C01-02	Tongue	76	76	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	22.1
C03-06	Oral cavity	118	117	99.2	1	0.8	0.0	0.0	0.8	0.0	99.2	15.7
C07-08	Salivary gland	32	31	96.9	1	3.1	0.0	0.0	3.1	0.0	96.9	56.5
C09	Tonsil	47	47	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	37.4
C11	Nasopharynx	169	169	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	28.4
C12-13	Hypopharynx	43	43	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	15.7
C15	Oesophagus	113	113	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	9.6
C16	Stomach	396	395	99.7	1	0.3	0.0	0.0	0.3	0.0	99.7	7.3
C18	Colon	425	424	99.8	1	0.2	0.0	0.0	0.0	0.2	100.0	19.4
C19-20	Rectum	249	247	99.2	2	0.8	0.0	0.0	0.4	0.4	99.6	24.0
C22	Liver	1455	1452	99.8	3	0.2	0.0	0.0	0.2	0.0	99.8	2.2
C23-24	Gall bladder	266	266	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	4.5
C25	Pancreas	158	158	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	3.4
C26	Gastrointestinal tract unspecified	140	140	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	1.4
C30-31	Nose/Sinuses	42	42	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	43.5
C32	Larynx	162	160	98.8	2	1.2	0.0	0.0	1.2	0.0	98.8	20.6
C33-34	Lung	3014	3009	99.8	5	0.2	0.0	0.0	0.1	0.1	99.9	4.9
C40-41	Bone	26	26	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	17.0
C43	Melanoma skin	50	50	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	42.2
C44	Other skin	292	289	99.0	3	1.0	0.0	0.0	0.3	0.7	99.7	74.4
C47+C49	Connective tissue	70	69	98.6	1	1.4	0.0	0.0	0.0	1.4	100.0	47.5
C50	Breast	830	821	98.9	9	1.1	0.0	0.0	1.0	0.1	99.0	59.0
C51	Vulva	30	30	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	61.2
C53	Cervix	1079	1064	98.6	15	1.4	0.0	0.0	0.6	0.7	99.4	63.6
C54	Corpus uteri	101	101	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	67.3
C56	Ovary	193	192	99.5	1	0.5	0.0	0.0	0.5	0.0	99.5	46.2
C60	Penis	70	69	98.6	1	1.4	0.0	0.0	1.4	0.0	98.6	60.7
C61	Prostate	171	170	99.4	1	0.6	0.0	0.0	0.0	0.6	100.0	49.6
C62	Testis	31	31	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	55.8
C64	Kidney	46	46	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	6.1
C65	Renal pelvis	39	38	97.4	1	2.6	0.0	0.0	0.0	2.6	100.0	5.5
C67	Urinary bladder	265	260	98.1	5	1.9	0.0	0.0	1.5	0.4	98.5	28.1
C70-72	Brain & nervous system	73	70	95.9	3	4.1	0.0	0.0	4.1	0.0	95.9	28.9
C73	Thyroid	133	133	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	59.3
C81	Hodgkin lymphoma	54	52	96.3	2	3.7	0.0	0.0	1.9	1.9	98.1	24.1
C82-85+C96	Non-Hodgkin lymphoma	368	366	99.5	2	0.5	0.0	0.0	0.3	0.3	99.7	25.5
C91	Lymphoid leukaemia	109	107	98.2	2	1.8	0.0	0.0	0.0	1.8	100.0	25.1
C92-94	Myeloid leukaemia	137	136	99.3	1	0.7	0.0	0.0	0.7	0.0	99.3	8.9
C95	Leukaemia unspecified	90	90	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	0.7

Other tables available for this registry:

- Table1:	Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Lampang, Thailand, 1990-2000 cases followed-up until 2003)
- Table2a:	Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site (Lampang, Thailand, 1990-2000 cases followed-up until 2003)
- Table3:	Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Lampang, Thailand, 1990-2000 cases followed-up until 2003)
- Table4:	Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Lampang, Thailand, 1990-2000 cases followed-up until 2003)
- Table5b:	Proportion (%) of cases and 5-year absolute survival by extent of disease and site (Lampang, Thailand, 1990-2000)

Registry chapter:

Consult the chapter in Cancer survival in developping countries (Volume II)